Loading
Latest filing published 27 Nov 2024 for Viracta Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Roger Pomerantz in Viracta Therapeutics, Inc., where the filings describe the role as board member. The record holds 13 filings, for trades running from 25 November 2021 to 25 November 2024.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 27 November 2024 came the latest disclosure, an option exercise in Viracta Therapeutics, Inc. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations